Phase II data show 5HT1D agonist MAP0004 is effective in Migraine « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
July 2008

M T W T F S S

« Jun Aug »

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30 31

Phase II data show 5HT1D agonist MAP0004 is effective in Migraine

Posted on July 16, 2008 by crimsoncanary

Phase II data published in the July issue of Current Medical Research and Opinion show MAP Pharmaceutical’s 5HT1D agonist MAP0004, an orally inhaled and self-administered therapy, to demonstrate efficace in migraine.

Filed under: Uncategorized | Tagged: 5-HT1D, 5HT1D, agonist, MAP, MAP-0004, MAP0004, phase II

« Akela Pharma to repeat Fentanyl TAIDUN tests at request of FDA Novo Nordisk submit new drug application for liraglutide in Japan »

Leave a Reply